Drug Neurology

Epidiolex

Payments companies reported to CMS as associated with Epidiolex. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$4.3Massociated payments (2023-2025)
6,455clinicians with associated payments
2companies reporting

By year

2023 $1.2M
2024 $1.4M
2025 $1.8M

Payments reported as associated with Epidiolex, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurology (Psychiatry & Neurology) $1.4M
Neurology With Special Qualifications In Child Neurology $1.3M
Epilepsy $636K
Family $198K
Clinical Neurophysiology $149K
Neurodevelopmental Disabilities (Pediatrics) $107K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Epidiolex

These are the largest totals companies reported as associated with Epidiolex. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
David Burdette Grand Rapids, MI Epilepsy $216,950.90
Selim Benbadis Tampa, FL Neurology (Psychiatry & Neurology) $193,287.71
Atiya Khan Fort Wayne, IN Neurology With Special Qualifications In Child Neurology $177,058.36
Janice Rodriguez Hernandez Guaynabo, PR Neurology With Special Qualifications In Child Neurology $137,374.41
Danielle Becker Columbus, OH Epilepsy $135,101.49
Jesus Pina Garza Nashville, TN Neurology With Special Qualifications In Child Neurology $109,022.95
Karen Keough Austin, TX Epilepsy $108,675.26
Raman Sankar Los Angeles, CA Neurodevelopmental Disabilities (Pediatrics) $102,739.89
James Wheless Memphis, TN Neurology With Special Qualifications In Child Neurology $99,032.49
Ann Segeren Stanford, CA Neurology With Special Qualifications In Child Neurology $79,893.12

Prescribed Epidiolex?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.